Interactions between antiarrhythmic drugs and food;Interacciones entre fármacos antiarrítmicos y alimentos

Nutricion Hospitalaria

Volumn 27, Issue 5, 2012, Pages 1399-1407

  Jauregui Garrido B ^a   Jauregui Lobera I ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

Author keywords

Antiarrhythmic drugs; Diet; Fibre; Food drugs interactions; Grapefruit juice; Medicinal plants

Indexed keywords

ANTIARRHYTHMIC AGENT;

BEVERAGE; BIOAVAILABILITY; DIET; DIETARY FIBER; FEEDING BEHAVIOR; FOOD DRUG INTERACTION; GRAPEFRUIT; HUMAN; MEDICINAL PLANT; META ANALYSIS; PHYSIOLOGY;

ANTI-ARRHYTHMIA AGENTS; BEVERAGES; BIOLOGICAL AVAILABILITY; CITRUS PARADISI; DIET; DIETARY FIBER; FOOD HABITS; FOOD-DRUG INTERACTIONS; HUMANS; PLANTS, MEDICINAL;

EID: 84867481588     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2012.27.5.5925     Document Type: Review

References (110)

1. Delpón E, García Cosío F. Fármacos antiarrítmicos. En: Tamargo J. (coord). Farmacología cardiovascular. Madrid: Acción Médica; 2009, pp. 15-38.
2. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 24: 129-147.
3. Delpón E, García Cosío F, Caballero R. Fármacos antiarrítmicos. En: Lorenzo P, Moreno A, Leza JC, Lizasoaín I, Moro MA (eds.). Velázquez. Farmacología General y Clínica. 17.a ed. Madrid: Editorial Médica Panamericana; 2004, pp. 377-396.
4. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342-349.
5. Kuehl P, Zhang J, Lin J, Lin Y, Lamba J, Assem M et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis for polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
6. Abernethy DR, Flockhart DA. Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. Circulation 2000; 101: 1749-1753.
7. Guía europea para la investigación de interacciones medicamentosas. CPMP/EWP/560/95; 1997.
8. Elvin AT, Cole AF, Pieper JA, Rolbin SH, Lalka D. Effect of food on lidocaine kinetics: mechanism of food-related alteration in high intrinsic clearance drug elimination. Clin Pharmacol Ther 1981; 30: 455-460.
9. Connolly SJ, Kates RE, Lebsack CS, Harrison DC, Winkle RA. Clinical pharmacology of propafenone. Circulation 1983; 68: 589-596.
10. Connolly S, Lebsack C, Winkle RA, Harrison DC, Kates RE. Propafenone disposition kinetics in cardiac arrhythmia. Clin Pharmac Ther 1984; 36: 163-168.
11. Hollmann M, Brode E, Hotz D, Kaumeier S, Kehrhahn OH. Investigations on the pharmacokinetics of propafenone in man. Arzneim.-Forsch./Drug Res 1983; 33: 763-770.
12. Siddoway LA, McAllister CB, Wang T, Bergstrand RH, Roden DM, Wilkinson GR et al. Polymorphic oxidative metabolism ofpropafenone in man. Circulation 1983; 68 (Suppl. 3): 64.
13. Axelson JE, Chang GLY, Kirsten EB, Mason WD, Lanman RC, Kerr CR. Food increases the bioavilability of propafenona. Br J Clin Pharmac 1987; 23: 735-741.
14. Koytchev R, Alken RG, Mayer O, Smith I, Greenwood M. Influence of food on the bioavailability and some pharmacokinetic parameters of diprafenone-a novel antiarrhythmic agent. Eur J Clin Pharmacol 1996; 50: 315-319.
15. Conard GJ, Ober RE. Metabolism of flecainide. Am J Cardiol 1984; 53: 41B-51B.
16. Perry JC, Garson A Jr. Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. Am Heart J 1992; 124: 1614-1621.
17. Tjandra-Maga TB, Verbesselt R, Van Hecken A, Mullie A, De Schepper PJ. Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man Br J Clin Pharmac 1986; 22: 309-316.
18. Berdaï D, Demotes-Mainard F, Phillip F, Vinçon G, Montels R, Necciari J, et al. Influence of food and body weight on the pharma cokinetics of penticainide. Fundam Clin Pharmacol 1994; 8: 453-457.
19. McKnight WD, Murphy ML. The effect of food on procainamide absorption. South Med J 1976; 69: 851-852.
20. Lee KH, Xu GX, Schoenhard GL, Cook CS. Mechanisms of food effects of structurally related antiarrhythmic drugs, disopyramide and bidisomide in the rat. Pharm Res 1997; 14: 1030-1038.
21. Pao LH, Zhou SY, Cook C, Kararli T, Kirchhoff C, Truelove J, et al. Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-administration: relationship with region-dependent intestinal absorption. Pharm Res 1998; 15: 221-227.
22. Cook CS, Zhang L, Osis J, Schoenhard GL, Karim A. Mechanism of compound- and species-specific food effects of structurally related antiarrhythmic drugs, dysopyramide and bidisomide. Pharm Res 1998; 15: 429-433.
23. Toothaker RD, Randinitis EJ, Nelson C, Kinkel AW, Goulet JR. The influence of food on the oral absorption of bevantolol. J Clin Pharmacol 1987; 27: 297-299.
24. Zaman R, Wilkins MR, Kendall MJ, Jack DB. The effect of food and alcohol on the pharmacokinetics of acebutolol and its metabolite, diacetolol. Biopharm Drug Dispos 1984; 5: 91-95.
25. Wang BO, Semple HA. Inhibition of metoprolol metabolism by amino acids in perfused rat livers. Insights into the food effect? Drug Metab Dispos 1997; 25: 287-295.
26. Plosker GL, Clissold SP. Controlled Release Metoprolol Formulations: A Review of Their Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Hypertension and Ischaemic Heart Disease. Drugs 1992; 43: 382-414.
27. Byrne AJ, McNeil JJ, Harrison PM, Louis W, Tonkin AM, McLean AJ. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions. Br J Clin Pharmacol 1984; 17 (Suppl. 1): 45S-50S.
28. Semple HA, Xia F. Interaction between propranolol and amino acids in the single-pass isolated, perfused rat liver. Drug Metab Dispos 1995; 23: 794-798.
29. Dongowski G, Neubert RH, Plätzer M, Schwarz MA, Schnorrenberger B, Anger H. Interaction between food components and drugs. Part 6: Influence of starch degradation products on propranolol transport. Pharmazie 1998; 53: 871-875.
30. Neubert R, Fritsch B, Dongowski G. Interactions between food components and drugs. Part 3. Interactions between pectin and propranolol. Pharmazie 1995; 50: 414-416.
31. Power JM, Morgan DJ, McLean AJ. Effects of sensory (teasing) exposure to food on oral propranolol bioavailability. Biopharm Drug Dispos 1995; 16: 579-589.
32. Chow HH, Lalka D. Pharmacokinetics of D-propranolol following oral, intra-arterial and intraportal administration: contrasting effects of oral glucose pretreatment. Biopharm Drug Dispos 1993; 14: 217-231.
33. Asdaq SM, Inamdar MN. Pharmacodynamic and pharmacokinetic interactions of propranolol with garlic (Allium sativum) in rats. Evid Based Complement Alternat Med 2011; ID 824042. DOI:10.1093/ecam/neq076.
34. Rietz B, Isensee H, Strobach H, Makdessi S, Jacob R Cardioprotective actions of wild garlic (Allium ursinum) in ischemia and reperfusion. Mol Cell Biochem 1993; 119: 143-150.
35. Mäntylä R, Männistö P, Nykänen S, Koponen A, Lamminsivu U. Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. Eur J Clin Pharmacol 1983; 24: 227-230.
36. Dorian P. Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther 2010; 15 (4 Suppl.): 15S-18S.
37. Shayeganpour A, Hamdy DA, Brocks DR. Effects of intestinal constituents and lipids on intestinal formation and pharmacokinetics of desethylamidodarone formed from amiodarone. J Pharm Pharmacol 2008; 60: 1625-1632.
38. Weitschies W, Wedemeyer RS, Kosch O, Fach K, Nagel S, Söderlind E et al. Impact of the intragastric location of extended reléase tablets on food interactions. J Control Release 2005; 108: 375-385.
39. Waldman SA, Morganroth J. Effects of food on the bioequivalence of different verapamil sustained-release formulations. J Clin Pharmacol 1995; 35: 163-169.
40. Hashiguchi M, Ogata H, Maeda A, Hirashima Y, Ishii S, Mori Y et al. No effect of high-protein food on the steroselective bioavalilability and pharmacokinetics of verapamil. J Clin Pharmacol 1996; 36: 1022-1028.
41. Kozloski GD, De Vito JM, Johnson JB, Holmes GB, Adams MA, Hunt TL. Bioequivalence of verapamil hydrochloride extended-release pellet-filled capsules when opened and sprinkled on food and when swallowed intact. Clin Pharm 1992; 11: 539-542.
42. Greenblattt DJ, Smith TW, Koch-Weser J. Bioavailability of drugs: the digoxin dilemma. Clin Pharmacokinet 1976; 1: 36-51.
43. Hess T, Krähenbühl A, Luisier J, Weiss M. Biological availability of digoxin and beta-methyl-digoxin administered in the fasting state of after meals. Schweiz Med Wochenschr 1981; 111: 1434-1440.
44. Tsutsumi K, Nakashima H, Kotegawa T, Nakano S. Influence of food on the absorption of beta-methyldigoxin. J Clin Pharmacol 1992; 32: 157-162.
45. Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JM. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 1989; 12: 357-362.
46. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juicedrug interactions. Br J Clin Pharmacol 1998; 46: 101-110.
47. Uno T, Yasui-Furukori N. Effect of grapefruit in relation to human pharmacokinetic study. Curr Clin Pharmacol 2006; 1: 157-161.
48. Panchagnula R, Bansal T, Varma MV, Kaul CL. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux. Pharmazie 2005; 60 (12): 922-927.
49. Ofer M, Wolffram S, Koggel A, Spahn-Langguth H, Langguth P. Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT? Eur J Pharm Sci 2005; 25: 263-271.
50. Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol 2010; 70: 645-655.
51. Owira PM, Ojewole JA. The grapefruit: an old wine in a new glass? Metabolic and cardiovascular perspectives. Cardiovasc J Afr 2010; 21: 280-285.
52. Kakar SM, Paine MF, Stewart PW, Watkins PB. 6'7'-Dihydroxybergamottin contributes to the grapefruit juice effect. Clin Pharmacol Ther 2004; 75: 569-579.
53. Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004; 4: 281-297.
54. Lin C, Ke X, Ranade V, Somberg J. The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition. Cardiology 2008; 110: 145-152.
55. Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, Tamai I. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther 2010; 332: 181-189.
56. de Castro WV, Mertens-Talcott S, Derendorf H, Butterweck V. Grapefruit juice-drug interactions: Grapefruit juice and its components inhibit Pglycoprotein (ABCB1) mediated transport of talinolol in Caco-2 cells. J Pharm Sci 2007; 96 (10): 2808-2817.
57. Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, et al. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther 2005; 77 (4): 291-301.
58. Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 2001; 12: 361-367.
59. Lilja JJ, Raaska K, Neuvonen PJ. Effects of grapefruit juice on the pharmacokinetics of acebutolol. Br J Clin Pharmacol 2005; 60: 659-663.
60. Libersa CC, Brique SA, Motte KB, Caron JF, Guédon-Moreau LM, Humbert L et al. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000; 49 (4): 373-378.
61. Aqel SM, Irshaid YM, Gharaibeh MN, Arafat TA. The effect of ethyl acetate extract of pomelo mix on systemic exposure of verapamil in rabbits. Drug Metab Lett 2011; 5 (2): 92-98.
62. Fuhr U, Müller-Peltzer H, Kern R, Lopez-Rojas P, Jünemann M, Harder S et al. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharmacol 2002; 58: 45-53.
63. Ho PC, Ghose K, Saville D, Wanwimolruk S. Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur J Clin Pharmacol 2000; 56: 693-698.
64. Zaidenstein R, Dishi V, Gips M, Soback S, Cohen N, Weissgarten J, Blatt A, Golik A. The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil. Eur J Clin Pharmacol 1998; 54: 337-340.
65. Uesawa Y, Takeuchi T, Mohri K. Publication bias on clinical studies of pharmacokinetic interactions between felodipine and grapefruit juice. Pharmazie 2010; 65: 375-378.
66. Guo LQ, Chen QY, Wang X, Liu YX, Chu XM, Cao XM et al. Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine. Curr Drug Metab 2007; 8: 623-630.
67. Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB et al. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juicefelodipine interaction. Am J Clin Nutr 2006; 83 (5): 1097-1105.
68. Goosen TC, Cillié D, Bailey DG, Yu C, He K, Hollenberg PF, Woster PM, Cohen L, Williams JA, Rheeders M, Dijkstra HP. Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. Clin Pharmacol Ther 2004; 76: 607-617.
69. Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR. Grapefruit juice-felodipine interaction: effect of naringin and 6',7'- dihydroxybergamottin in humans. Clin Pharmacol Ther 1998; 64: 248-256.
70. Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice-felodipine interaction in the elderly. Clin Pharmacol Ther 2000; 68: 28-34.
71. Takanaga H, Ohnishi A, Matsuo H, Murakami H, Sata H, Kuroda K et al. Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharmacol 2000; 49: 49-58.
72. Bailey DG, Arnold JM, Bend JR, Tran LT, Spence JD. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol 1995; 40: 135-140.
73. Sica DA. Interaction of grapefruit juice and calcium channel blockers. Am J Hypertens 2006; 19: 768-773.
74. Parker RB, Yates CR, Soberman JE, Laizure SC. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy 2003; 23: 979-987.
75. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001; 70: 311-316.
76. Uesawa Y, Mohri K. Hesperidin in orange juice reduces the absorption of celiprolol in rats. Biopharm Drug Dispos 2008; 29: 185-188.
77. Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol 2005; 61: 337-340.
78. Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol. Clin Pharmacol Ther 2004; 75: 184-190.
79. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001; 69: 14-23.
80. Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther 2003; 73: 529-537.
81. Piao YJ, Choi JS. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats. Arch Pharm Res 2008; 31: 518-522.
82. Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 302: 645-650.
83. Mervaala EM, Malmberg L, Teräväinen TL, Laakso J, Vapaatalo H, Karppanen H. Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats. Br J Pharmacol 1998; 123: 195-204.
84. Gurley BJ, Swain A, Williams DK, Barone G, Battu SK. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008; 52: 772-779.
85. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 338-345.
86. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 2006; 34: 69-74.
87. Miller LG, Murray WJ, editors. Herbal medicinals: A clinicians' guide. New York: Pharmaceutical Products Press; 1998.
88. nd ed. London: The Pharmaceutical Press; 2002.
89. Valli G, Giardiana EG. Benefits, adverse effects and drug interactions of herbal therapics with cardiovascular effects. J Am Coll Cardiol 2002; 38: 1083-1095.
90. McRae S. Elevated serum digoxin levels in a patient taking digoxin and siberian ginseng. Can Med Assoc J 1996; 155: 293-295.
91. Awang DV. Siberian ginseng toxicity may be a case of mistaken identity. Can Med Assoc J 1996; 155: 1237.
92. Trunzler G, Schuler E. Comparative studies on the effects of a crataegus extract, digitoxin, digoxin and q-strophantin in the isolated heart of homoiothermals. Azzneim- Forsch 1962; 12: 198-202.
93. Tankanow R, Tamer HR, Stretman DS, Smith GS, Welton JL, Annesley T et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol 2003; 43: 637-642.
94. Shinozuka K, Umegaki K, Kubota Y, Tanaka N, Mizuno H, Yamauchi J et al. Feeding of Ginkgo biloba extract (GBE) enhances gene expres- sion hepatic cytochrome P-450 and attenuates the hypotensive effects of nicardipine in rats. Life Sci 2002; 70: 2783-2792.
95. Wielepp JP, Fricke E, Horstkotte D, Burchert W. Effect of caffeine on myocardial blood flow during pharmacological vasodilation. Z Kardiol 2005; 94: 128-132.
96. Onrat E, Kaya D, Barutçu I. Atrioventricular complete heart block developed due to verapamil use together with honey consumption. Anadolu Kardiyol Derg 2003; 3: 353-354.
97. Johnson BF, Rodin SM, Hoch K, Shekar V. The effect of dietary fiber on the bioavailability of digoxin in capsules. J Clin Pharmacol 1987; 27: 487-490.
98. Bustrack JA, Katz JD, Hull JH, Foster JR, Hammond JE, Christenson RH. Bioavailability of digoxin capsules and tablets: effect of coadministered fluid volume. J Pharm Sci 1984; 73: 1397-1400.
99. Nordström M, Melander A, Robertsson E, Steen B. Influence of wheat bran and of a bulk-forming ispaghula cathartic on the bioavailability of digoxin in geriatric in-patients. Drug Nutr Interact 1987; 5: 67-69.
100. Mulrow JP, Mulrow CD, McKenna WJ. Pyridoxine and amiodarone- induced photosensitivity. Ann Intern Med 1985; 103: 68-69.
101. Kaufmann G. Pyridoxine against amiodarone-induced photosensitivity. Lancet 1984; 1 (8367): 51-52.
102. Guerciolini R, Del Favero A, Cannistraro S. Amiodaroneinduced photosensitivity and pyridoxine. Lancet 1984; 1 (8383): 962.
103. Gonzalez JP, Valdivieso A, Calvo R, Rodríguez-Sasiaín JM, Jimenez R et al. Influence of vitamin C on the absorption and first pass metabolism of propranolol. Eur J Clin Pharmacol 1995; 48: 295-297.
104. Bailey DG, Arnold JM, Spence JD. Grapefruit juice and drugs. How significant is the interaction? Clin Pharmacokinet 1994; 26: 91-98.
105. Edgar B, Regårdh CG, Johnsson G, Johansson L, Lundborg P, Löfberg I, et al. Felodipine kinetics in healthy men. Clin Pharmacol Ther 1985; 38: 205-211.
106. Blychert E, Edgar B, Elmfeldt D, Hedner T. A population study of the pharmacokinetics of felodipine. Br J Clin Pharmacol 1991; 31: 15-24.
107. de Andrés S, Lucena A, de Juana P. Interactions between foodstuffs and statins. Nutr Hosp 2004; 19: 195-201.
108. Observatorio del consumo y la distribución alimentaria. Monográfico zumos y pomelo. Madrid: Ministerio de agricultura, alimentación y medio ambiente; 2010.
109. Tres JC. Interacción entre fármacos y plantas medicinales. An Sist Sanit Navar 2006; 29: 233-252.
110. Sanfélix J, Palop V, Rubio E, Martínez-Mir I. Consumo de hierbas medicinales y medicamentos. Aten Primaria 2011; 28: 311-314.